美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Corgi Genomics & Precision Medicine ETF

36.60

+0.08370.23%

成交量：1,366

成交额：4.95万

市值：128.09万

市盈率：- -

高：36.60

开：36.20

低：36.18

收：36.51

52周最高：39.65

52周最低：23.88

股本：3.50万

流通股本：3.50万

量比：0.66

换手率：3.90%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

福泰制药Povetacicept加速审批在望，FDA目标决定日期锁定11月30日

Povetacicept治疗IgA肾病三期Rainier研究结果发表于《新英格兰医学杂志》并在2026年美国肾脏病学会肾脏周上公布，支持其同类最佳潜力

阿尔尼拉姆制药公司：安全性与耐受性表现令人鼓舞，有望实现每年两次给药

阿尔尼拉姆制药公司：在监管协调前提下，计划于2027年开展安慰剂对照关键性研究

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/GNMX"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GNMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","market":"US","secType":"STK","nameCN":"Corgi Genomics & Precision Medicine ETF","latestPrice":36.597,"timestamp":1792785600000,"preClose":36.5133,"halted":0,"volume":1366,"delay":0,"changeRate":0.002292315402880603,"floatShares":35000,"shares":35000,"eps":0,"marketStatus":"休市中","change":0.0837,"latestTime":"10-23 16:00:00 EDT","open":36.2,"high":36.597,"low":36.1842,"amount":49530,"amplitude":0.011305,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1302235200000,"exchange":"CBOE","adjPreClose":36.5133,"nav":36.52,"aum":1325800,"bidAskSpread":0,"volumeRatio":0.6553445107952776,"impliedVol":0.154,"impliedVolPercentile":0.3273},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","floatShares":35000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6553445107952776,"shares":35000,"dividePrice":0,"high":36.597,"amplitude":0.011305,"preClose":36.5133,"low":36.1842,"week52Low":23.88,"pbRate":"--","week52High":39.645,"institutionHeld":0,"latestPrice":36.597,"eps":0,"divideRate":0,"volume":1366,"delay":0,"ttmEps":0,"open":36.2,"prevYearClose":25.56,"prevWeekClose":35.66,"prevMonthClose":38.3481,"prevQuarterClose":38.3481,"fiveDayClose":35.66,"twentyDayClose":38.003,"sixtyDayClose":30.3183},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GNMX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GNMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GNMX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GNMX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1187257621","title":"福泰制药Povetacicept加速审批在望，FDA目标决定日期锁定11月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=1187257621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187257621?lang=zh_cn&edition=fundamental","pubTime":"2026-10-24 01:45","pubTimestamp":1792777546,"startTime":"0","endTime":"0","summary":"福泰制药（Vertex Pharmaceuticals）旗下在研药物Povetacicept的加速审批进程正稳步推进，美国食品药品监督管理局（FDA）设定的处方药用户付费法案（PDUFA）目标决定日期为11月30日。该日期标志着监管机构对该药物加速批准申请作出审评结论的关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU2236285917.USD","GNMX","LU2362541273.HKD","BK4588","LU1674673428.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU2462157665.USD","LU0417517546.SGD","SG9999001176.SGD","BK4139","IE00B19Z9Z06.USD","LU2089984988.USD","LU2324357040.USD","LU2456880835.USD","BK4567","BK4585","IE00B19Z3B42.SGD","LU0109394709.USD","LU2417539215.USD","IE00BZ9MQY76.HKD","TBXU","LU0058720904.USD","BBH","LU0256863811.USD","LU1069344957.HKD","IE00B2B36J28.USD","BK4532","LU1585245621.USD","LU1674673691.USD","IE00B894F039.SGD","LU1093756325.SGD","LU2362541513.USD","PBE","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","LU1035775433.USD","IE00B19Z9P08.USD","LU0823416689.USD","IE0002270589.USD","LU0289739699.SGD","IBB","LU2237438978.USD","IDNA","BK4533","LU1430594728.SGD","LU2468319806.SGD","SG9999001176.USD","LU0079474960.USD","LU0234570918.USD","LU0061475181.USD","VRTX","LU0320765992.SGD","SGXZ57979304.SGD","IE0009355771.USD","BIB","LU2362540622.SGD","IE00BJT1NW94.SGD","LU1778281490.HKD","IBBQ","LU1093756168.USD","SG9999013999.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110302816","title":"Povetacicept治疗IgA肾病三期Rainier研究结果发表于《新英格兰医学杂志》并在2026年美国肾脏病学会肾脏周上公布，支持其同类最佳潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1110302816","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110302816?lang=zh_cn&edition=fundamental","pubTime":"2026-10-24 01:43","pubTimestamp":1792777388,"startTime":"0","endTime":"0","summary":"Povetacicept治疗IgA肾病三期Rainier研究结果发表于《新英格兰医学杂志》并在2026年美国肾脏病学会肾脏周上公布，支持其同类最佳潜力","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","BBH","LU2456880835.USD","BK4139","IE00B2B36J28.USD","IE00B19Z9P08.USD","SG9999001176.USD","LU0109394709.USD","LU0061475181.USD","LU0889565916.HKD","LU0289739699.SGD","LU0417517546.SGD","IE00BFTCPJ56.SGD","BK4532","LU2417539215.USD","BK4585","LU0234570918.USD","LU1093756168.USD","IE00BZ9MQY76.HKD","IBB","LU0079474960.USD","SG9999013999.USD","LU1674673428.USD","IE00B19Z3581.USD","SG9999001176.SGD","IE00BJT1NW94.SGD","IE0009355771.USD","IE00B19Z3B42.SGD","BIB","BK4588","BK4533","IE0002270589.USD","LU0256863811.USD","LU2468319806.SGD","LU2324357040.USD","LU1069344957.HKD","LU1093756325.SGD","LU2236285917.USD","LU2362540622.SGD","LU2362541513.USD","IBBQ","BK4567","IE00B894F039.SGD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","TBXU","LU0823416689.USD","GNMX","LU0058720904.USD","PBE","LU1035775433.USD","LU2237438978.USD","IDNA","LU1430594728.SGD","LU1585245621.USD","IE0002141913.USD","LU2362541273.HKD","LU1778281490.HKD","VRTX","LU0320765992.SGD","LU2462157665.USD","LU1674673691.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121876045","title":"阿尔尼拉姆制药公司：安全性与耐受性表现令人鼓舞，有望实现每年两次给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1121876045","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121876045?lang=zh_cn&edition=fundamental","pubTime":"2026-10-23 15:47","pubTimestamp":1792741628,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司：安全性与耐受性结果令人振奋，每年两次给药方案潜力初显","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","LU0882574055.USD","PBE","ALNY","BK4585","LU0114720955.EUR","BK4139","BK4548","GNMX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122564098","title":"阿尔尼拉姆制药公司：在监管协调前提下，计划于2027年开展安慰剂对照关键性研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1122564098","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122564098?lang=zh_cn&edition=fundamental","pubTime":"2026-10-23 15:47","pubTimestamp":1792741627,"startTime":"0","endTime":"0","summary":"阿尔尼拉姆制药公司：在监管协调前提下，计划于2027年开展安慰剂对照关键性研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","GNMX","LU0320765992.SGD","LU0889565916.HKD","ALNY","LU0114720955.EUR","PBE","BK4548","LU0109394709.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":33,"pageCount":1,"totalSize":129,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/GNMX\",params:#limit:6,delay:false,,,undefined,":[]}}